Yili Chuanning Biotechnology Co., Ltd. Class A

Yili Chuanning Biotechnology Co., Ltd. Class A

SSZSE:301301
7.51
CNY
-0.02
(-0.27%)
0.22EPS
37.22P/E
18.28BMarket Cap
Apr 06Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.67
1.41
1.75
1.74
1.95
2.15
2.59
2.04
1.82
Basic EPS, GAAP
0.19
0.04
0.11
0.06
0.21
0.42
0.63
0.34
0.22
Free Cash Flow per Basic Share
0.14
-0.1
0.27
0.4
0.33
0.42
0.79
0.2
- -
Dividend per Share
- -
- -
0.03
0.09
0.07
0.13
0.25
0.28
0.18
Book Value per Share
2.17
2.22
2.33
2.39
2.79
3.13
3.55
3.62
3.6
Tangible Book Value per Share
2.06
2.09
2.2
2.25
2.66
3.01
3.44
3.52
3.5
Basic Weighted Avg Shares
2,000
2,223
2,082
1,856
1,960
2,239
2,223
2,262
2,227
Sales/Revenue/Turnover
3,349
3,143
3,649
3,232
3,821
4,823
5,758
4,616
4,063
Operating Margin (%)
17.69
11.15
12.72
12.63
18.53
25.81
30.49
22.11
16.36
Depreciation Expense
446
456
491
524
548
550
558
587
- -
Net Income, GAAP
390
91
229
111
412
941
1,400
769
490
Effective Tax Rate (%)
- -
18.18
17.05
16.96
15.61
15.85
16.4
18.15
18.18
Profit Margin (%)
11.64
2.91
6.28
3.45
10.77
19.5
24.32
16.66
12.06
Working Capital
-2,507
-2,343
914
653
1,820
1,421
2,197
2,465
2,587
LT Debt
- -
- -
2,850
2,095
1,438
545
597
470
450
Total Equity
4,366
4,431
4,666
4,777
6,210
6,973
7,916
8,108
8,059
Return on Invested Capital (%)
- -
2.19
3.47
2.14
5.13
10.24
15.38
8.36
5.37
Return on Capital (%)
- -
25.63
17.89
9.74
5.93
11.03
15.75
8.56
5.67
Return on Common Equity (%)
- -
2.08
5.04
2.36
7.5
14.29
18.85
9.62
6.2

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
771
759
636
LT Borrowings
- -
- -
- -
LT Finance Leases
448
447
450
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,230
2,232
2,232
Market Capitalization
23,862
17,724
18,282

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
4,191
4,242
4,332
Cash, Cash Equivalents & STI
664
1,046
885
Accounts Receivable, Net
1,148
1,040
959
Inventories
1,322
1,402
1,686
Total Current Liabilities
1,631
1,769
1,745
Payables & Accruals
- -
- -
- -
ST Debt
771
759
636
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
12.12%
2.42%
Free Cash Flow
- -
15.44%
-74.16%
Net Income, GAAP
- -
70.11%
-45.08%
Sales/Revenue/Turnover
- -
6.51%
-19.83%
Total Cash Common Dividend
- -
76.66%
14.13%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,523
1,672
1,261
1,302
5,758
2025
1,297
1,052
- -
1,180
4,616
2026
1,094
1,003
785
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.19
0.14
0.15
0.63
2025
0.13
0.07
- -
0.07
0.34
2026
0.05
0.07
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.23
- -
- -
0.25
2025
- -
0.27
- -
- -
0.28
2026
- -
0.17
- -
- -
- -

Company Description

CEO
Xu Heng Deng
Full Time Employees
3,126
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Korgas China
IPO Date
Dec 27, 2022
Website
klcnsw.com
Business
Yili Chuanning Biotechnology Co., Ltd. is a China-based biomanufacturing enterprise engaged in the research, development, production, and commercialization of biological fermentation products, pharmaceutical intermediates, and synthetic biology materials. Founded in 2010 and headquartered in Yining, Xinjiang Uygur Autonomous Region, China, the company operates as a key subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd. and trades on the Shenzhen Stock Exchange. The company offers a diversified biomanufacturing portfolio structured around industrial-scale microbial fermentation and synthetic biology platforms. Its core products and services comprise: antibiotic intermediates, including erythromycin thiocyanate, 6-aminopenicillanic acid (6-APA), penicillin G potassium industrial salt, 7-aminocephalosporanic acid (7-ACA), and deacetyl-7-aminocephalosporanic acid (D-7-ACA); cosmetic and high-end personal care active ingredients, including bio-synthesized alpha-bisabolol, ergothioneine, ectoine, squalane, phytosphingosine, and ceramides; nutritional, healthcare, and animal feed ingredients, including 5-hydroxytryptophan (5-HTP), inositol, and coenzyme Q10; bio-based materials, including polyhydroxyalkanoates (PHA) biodegradable polymers; biological agricultural formulations and biopesticide raw materials; and technical bioprocess services, including chassis cell engineering, automated high-throughput strain screening, and contract biomanufacturing. Yili Chuanning Biotechnology operates large-scale manufacturing facilities in Xinjiang to leverage local agricultural feedstocks and competitive energy resources, complemented by an advanced synthetic biology innovation center operated by its subsidiary, Shanghai Recom Biotechnology R&D Co., Ltd., in Shanghai. The company serves pharmaceutical manufacturers, personal care brands, and agricultural enterprises across China as well as export destinations in Asia, Europe, and the Americas. In recent strategic developments, the company has advanced its dual-wheel growth strategy combining traditional fermentation with synthetic biology, commissioning its dedicated synthetic biology industrial production facility in Gongliu, Xinjiang, to commercialize high-margin specialty ingredients such as bisabolol and ergothioneine. The company entered into a strategic partnership with Beijing PhaBuilder Biotechnology Co., Ltd. to establish a joint venture, Xinjiang Weining Biotechnology Co., Ltd., dedicated to scaling the production of medical-grade and industrial polyhydroxyalkanoates (PHA). Furthermore, the company partnered with Shanghai Jincheng Technology to deploy artificial intelligence algorithms and machine learning models for real-time fermentation control and enzyme engineering, while expanding international market access through a commercial cooperation agreement with South Korea-based ACTIVON to distribute functional cosmetic active ingredients globally.